Evidence map›Paper›PMID 38947586›Full record

ArticleCureus2024

Neoadjuvant Immunotherapy Effectiveness in Patients With Microsatellite Instability-High (MSI-H) Gastric Cancer.

Viacheslav A Chubenko, Alexander Y Navmatulya, Ivan A Gerk, Artem A Sarmatov, Vitaliy V Egorenkov, Ksenia A Shelekhova, Evgeny N Zykov, Vera V Chernobrivceva, Nikita M Volkov, Vladimir M Moiseyenko

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Viacheslav A ChubenkoDepartment of Chemotherapy, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.
Alexander Y NavmatulyaDepartment of Abdominal Surgery, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.
Ivan A GerkDepartment of Chemotherapy, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.
Artem A SarmatovDepartment of Chemotherapy, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.
Vitaliy V EgorenkovDepartment of Surgery, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.
Ksenia A ShelekhovaDepartment of Pathology, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.
Evgeny N ZykovDepartment of Radioisotope, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.
Vera V ChernobrivcevaDepartment of Radiology, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.
Nikita M VolkovDepartment of Medical and Radiation Therapy, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.
Vladimir M MoiseyenkoDepartment of the Director, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose This research work evaluates monotherapy with checkpoint inhibitors (CPI). as a neoadjuvant treatment for patients with Microsatellite Instability-High (MSI-H) locally advanced gastric cancer. Methods Here we present the results of the retrospective study from Napalkov Cancer Center over 4.5 years on patients with MSI-H locally advanced gastric cancer. A total of 566 patients were analyzed, 18 of whom were included in the research, focusing on clinical response rate, surgical pathology, 'watch and wait' strategy, and safety outcomes on an exploratory basis. Patients were assigned to four to eight neoadjuvant cycles of CPI, followed by surgery. Results The objective response to neoadjuvant CPI in patients with MSI-H gastric cancer was 77.8%. Complete response was achieved in five (27.8%) and partial response in nine (50%) patients, accordingly. Surgery was performed on 14 patients. Complete margin-free (R0) resection rates were 100%. Downstaging was observed in 12 out of 14 patients. Histopathologic complete response rates (pathologic complete response or Tumor Regression Grade-major response (TRG1)) were achieved in eight (57.1%) patients. No disease progression was detected with a median follow-up of 33.7 months (4.4-55.7 months). Clinically significant adverse events were not observed. Conclusion CPI in a neoadjuvant setting for patients with MSI-H locally advanced gastric cancer is highly effective and safe.

Indexed as

gastric cancerimmunotherapymonotherapymsi-hneoadjuvant

Identifiers

PMID38947586
PMCPMC11214122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.